A retrospective analysis of pharmacotherapy in Kazakhstan: Assessment of the rational prescription and use of antibiotics in the nephrology department of a multidisciplinary hospital

2022

Full text Open access: Gold Metadata (CSL-JSON)
DOI 10.29333/ejgm/12576
Data confidence 85 high
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

Introduction: The rapid development of the pharmaceutical industry has increased the need to assess and monitor the use of medicines. Thus, necessitates the importance of monitoring the appropriate use of medicines including antimicrobials. Objective: Pharmacoeconomic analysis of pharmacotherapy in the nephrology department at a multidisciplinary hospital. Methods: The study is a retrospective analysis of medicine use and expenditure. The study utilized the ABC-VEN analysis of medical use and the WHO-AWaRe-2021 analysis of antibiotic use, to determine the prescription and financial trends of the nephrology department (30 beds) of a multidisciplinary regional hospital (total 844 beds) in Turkestan, Kazakhstan 2018-2021. Results: The analyzed costs of drugs included 116 international nonproprietary names prescribed to patients from the nephrology department during the study period. In total, pharmacotherapy costs increased by 52.6% in 2021 compared to 2018. Five INN drugs were purchased without their inclusion in the Kazakhstan National Medicinal Formulary, such as atropine sulfate, sodium bicarbonate, sodium chloride (crystalline salt), nitroxoline, and nitrofural. The pharmacoeconomics analysis of antibiotics usage for 2018-2021 showed a sharp increase in the%age of costs. Conclusion: The study showed an increase in funding for pharmacotherapy in the department of nephrology, which increases the availability of medicines. However, the trend in prescribing drugs with poor evidence base level, and the increase in the proportion of antibiotic prescription, require immediate intervention including the utilization of clinical pharmacy services for regular assessment of the pharmacoeconomic feasibility of antibiotic therapy. This will improve the quality of medical care and reduce the financial costs.